Table 1.
Clinicopathological characteristics of patients in the training and validation cohorts.
| Characteristic | Training(n = 122) | Validation(n = 60) | P value |
|---|---|---|---|
| Age, mean ± SD, years | 39.36 ± 12.31 | 40.12 ± 11.16 | 0.689¶ |
| Patients | 0.192§ | ||
| Non-RAIT failure | 72 (59.02) | 42 (70.00) | |
| RAIT failure | 50 (40.98) | 18 (30.00) | |
| Gender | 0.173§ | ||
| Male | 41 (33.61) | 14 (23.33) | |
| Female | 81 (66.39) | 46 (76.67) | |
| CI | 0.428§ | ||
| Positive | 70 (57.38) | 30 (50.00) | |
| Negative | 52 (42.62) | 30 (50.00) | |
| ETE | 0.762§ | ||
| Positive | 30 (24.59) | 16 (26.67) | |
| Negative | 92 (75.41) | 44 (73.33) | |
| Diameter, median ± interquartile range, cm | [1.50(1.00, 2.50)] | [1.50(1.00, 2.50)] | 0.765‖ |
| CLN metastasis | 0.091§ | ||
| N0 | 7 (5.74) | 8 (13.33) | |
| NX | 115 (94.26) | 52 (86.67) | |
| LLN metastasis | 0.151§ | ||
| N0 | 45 (36.89) | 29 (48.33) | |
| NX | 77 (63.11) | 31 (51.67) | |
| Number of LLN metastasis, median ± interquartile range | [3.00(0.00, 7.00)] | [1.50(0.00, 6.00)] | 0.124‖ |
| I-131 dosage, median ± interquartile range, mCi | [150(140.00, 150)] | [150(140, 150)] | 0.099‖ |
| Time from surgery to RAIT, median ± interquartile range, months | [4.00(3.00, 5.00)] | [4.00(2.25, 5.75)] | 0.652‖ |
| Previous thyroid disease | 0.869§ | ||
| Positive | 41 (33.61) | 21 (35.00) | |
| Negative | 81 (66.39) | 39 (65.00) | |
| Multifocality of lesions | 0.873§ | ||
| Positive | 75 (61.48) | 36 (60.00) | |
| Negative | 47 (38.52) | 24 (40.00) | |
| Follow-up time, median ± interquartile range, months | [14.00(8.75, 23.25)] | [11.50(9.00, 20.75)] | 0.683‖ |
| Maximum diameter of metastatic LLN, median ± interquartile range, mm | [10.50(0.00, 16.00)] | [7.00(0.00, 15.00)] | 0.081‖ |
| Tg before RAIT, median ± interquartile range, IU/ml | [2.80(0.13, 10.82)] | [2.67(0.21, 11.04)] | 0.983‖ |
| TGAb before RAIT, median ± interquartile range, IU/ml | [0.76(0.19, 5.50)] | [0.78(0.19, 3.88)] | 0.942‖ |
| Tg after RAIT, median ± interquartile range, IU/ml | [0.09(0.02, 0.91)] | [0.09(0.04, 0.53)] | 0.905‖ |
| TGAb after RAIT, median ± interquartile range, IU/ml | [0.90(0.29, 2.24)] | [0.90(0.29, 5.19)] | 0.832‖ |
Data expressed as n (%), unless otherwise stated.
CLN, central lymph node; CI, capsular invasion; ETE, extrathyroidal extension; LLN, lateral neck lymph node; RAIT, radioactive iodine therapy; TG, thyroglobulin; TGAb, anti-thyroglobulin antibodies. ¶ By the Independent samples t-test. § By the Chi-square test. ‖ By the Mann–Whitney U test.